TREX1 Inhibitor Assays
TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or
DDX3 inhibitors antiviral therapeutics
DDX3 inhibitors could unlock new treatments for viral diseases. The human immune response is extraordinary and incredibly complex. As the first line of defense against pathogens and foreign DNA, the innate response acts quickly. Viruses activate innate immunity as the host has proteins that recognize viral components. The innate immune response relies on several cell
cGAS Phase II Press Release Graphic
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
Performing a Kinase Assay Kit in a Lab
Kinases are essential players in cellular functions such as cell signaling, cellular transport, and protein regulation. For these reasons, many kinases are innate immunity targets. A kinase assay kit is ideal whether used for drug screening and dose-response measurements or detection when studying a particular cellular pathway. A universal ADP assay allows researchers to screen
Small GTPase Modulation
Cancer is complex, which makes determining the culprit as well as individual treatment extremely challenging. A variety of cancer types exist with a multitude of contributors. As the second leading cause of death in the US, cancer has been a target scientists have been battling for decades. When DNA is damaged or mutations occur, cells
TREX1 Press Release Graphic
The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway. Madison, WI – March 2021 – BellBrook Labs has been awarded a $300,000 Phase I Small
Researcher Using An ADP Assay
An ADP assay can be used to study the activity of enzymes that phosphorylate substrates leading to signaling events in the body. One of a variety of post-translational modifications, protein phosphorylation regulates a diverse group of cellular functions. In cancer, abnormal phosphorylation events often play a role in proliferation, survival, motility, metabolism, and angiogenesis.1 PI3K
Inhibitors of ENPP1 SLAS Discovery
BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the
GMP Assay for PDE Inhibitor Discovery
A universal GMP assay to aid in PDE research and potential COVID-19 disruption. – Phosphodiesterase enzymes (PDEs) modulate pathways throughout the body. Since unregulated PDEs contribute to disease in many cases, it makes sense therapies that inhibit these enzymes have the potential to treat several different ailments. These include cardiovascular and respiratory issues, diabetes, fibrotic
SLAS 2021
BellBrook Labs will be exhibiting at SLAS 2021, January 25-27. Due to the pandemic, this year’s meeting will, of course, be virtual. Although, we are sad that we won’t be able to meet with you in person this year there are still plenty of opportunities to interact. We will have a virtual booth that is
TOP